Before we begin, this is not financial advice, I own this stock, and it’s important to realize the bias that comes with that.
But with that out of the way let me introduce you “retail traders” into what I believe is an incredibly undervalued Infectious disease, psychedelics, and cannabinoid bio tech firm Revive Therapeutics (RVVTF)
I could talk up this stock all day, but who gives a damn about Reddit user SunnySideSaLum. Although you should care about what Forbes said in their recent article covering the company. Here’s a shorter summary (link attached if you’d like to read the whole thing)
“ Revive’s would-be Covid treatment hinges on Bucillamine, which has been approved for use in South Korea and Japan for rheumatoid arthritis for the past 30 years. Bucillamine displays strong evidence in vitro of preventing SARS-COV-2 virus docking onto the ACE2 receptors, which is the primary gateway of the SARS-COV-2 virus into human cells. Research published on July 1, 2021 confirms thiol-based mucolytics, which are similar to Bucillamine, also displayed potent inhibition of SARS-CoV-2-ACE2 binding via disulfide reduction.
So, unlike the antiviral drugs being developed by the larger pharmaceutical companies that seek to address viral replication itself, Bucillamine may address that while also preventing the SARS-COV-2 virus from entering host cells.
Revive has recently decided to incorporate viral load testing for a minimum of 300 patients that will be enrolled in the current Phase 3 study. The viral load will allow Revive to quantify the speed at which Bucillamine can reduce viral infection of patients throughout the course of treatment, thus allowing to understand the most optimal time to introduce Bucillamine in the treatment course and provide confidence in the potential utility and effectiveness of Bucillamine in Covid.
Should the company’s goal of reducing viral load testing prove to be effective, Bucillamine could be in a favorable position to receive emergency use authorization (EUA) from the FDA. If it were approved, it is a strong indication that Bucillamine can indeed arrest viral load directly, not just treat Covid symptoms. Ideally, regulators would like to see proof of both mechanisms of action at work to declare a heightened baseline of efficacy. “
Their CEO Micheal Frank ended with this …
“We recognize the market opportunity for Bucillamine and we are in discussions with our manufacturing partners to ensure that billions of Bucillamine tablets can be made available in 2022 to support our future commercialization partners and the millions of people globally,” Frank added.
If you have more questions and would like to see fancy graphs please go to the RVVTF subreddit, there are great guys there who are much more knowledgeable then me and can answer a lot of your questions.
In conclusion, I’m not one to gamble, but if there’s a Penny stock to gamble on, for me, it’s most certainly this one. The upsides of this company EVEN IF THEY DON’T GET EUA are impressive. I’ll be holding this one for a while.
RVVTF: one pill to save us all:)
Submitted November 30, 2021 at 02:13AM by SunnySideSaLum https://ift.tt/3xzOUXO
